Who to call at TuHURA Biosciences, and when

Fundz watches for the moments TuHURA Biosciences starts buying, and tells you who to reach.

An alert the day TuHURA Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at TuHURA Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TuHURA Biosciences. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

TuHURA Biosciences Enters Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Jul 08, 2024

Contract Type

agreement

TampaBiotechnologyHealthcareHealth CareTherapeutics

Description

TuHURA Biosciences, Inc. has entered into an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset. The agreement involves the potential addition of KVA12123 to TuHURA's pipeline as a Phase 2 ready, novel checkpoint inhibitor.

Company Information

Company

TuHURA Biosciences

Location

10500 University Center Drive

Tampa, Florida, United States

About

Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.